The Effect of Tocilizumab on Inflammatory Markers in Patients Hospitalized with Serious Infections. Case Series and Review of Literature

Background: The human anti-IL-6 receptor antibody tocilizumab (TCZ) has been approved for the treatment of rheumatoid arthritis (RA) and giant cell arteritis (GCA). It is observed that CRP levels drop quickly after starting TCZ treatment. This may lead to misinterpretation of laboratory results when...

Descripción completa

Detalles Bibliográficos
Autores principales: Berman, Mark, Ben-Ami, Ronen, Berliner, Shlomo, Anouk, Marina, Kaufman, Ilana, Broyde, Adi, Borok, Sara, Elkayam, Ori
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003879/
https://www.ncbi.nlm.nih.gov/pubmed/33804790
http://dx.doi.org/10.3390/life11030258

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8003879/
https://www.ncbi.nlm.nih.gov/pubmed/33804790
http://dx.doi.org/10.3390/life11030258

Ejemplares similares